Brokerages Expect Amneal Pharmaceuticals Inc (AMRX) Will Post Quarterly Sales of $465.95 Million

Wall Street analysts predict that Amneal Pharmaceuticals Inc (NYSE:AMRX) will announce $465.95 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Amneal Pharmaceuticals’ earnings. The highest sales estimate is $474.50 million and the lowest is $441.20 million. Amneal Pharmaceuticals reported sales of $462.33 million in the same quarter last year, which would suggest a positive year over year growth rate of 0.8%. The firm is expected to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Amneal Pharmaceuticals will report full-year sales of $1.91 billion for the current fiscal year, with estimates ranging from $1.82 billion to $1.96 billion. For the next year, analysts forecast that the business will post sales of $1.97 billion, with estimates ranging from $1.86 billion to $2.04 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.07). The business had revenue of $446.00 million during the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year.

Several equities analysts have commented on AMRX shares. Cantor Fitzgerald reissued a “buy” rating and set a $35.00 price objective on shares of Amneal Pharmaceuticals in a research report on Thursday, February 28th. Svb Leerink lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $16.00 to $12.00 in a research report on Friday, March 8th. Raymond James raised Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price objective for the company in a research report on Tuesday. They noted that the move was a valuation call. SunTrust Banks started coverage on Amneal Pharmaceuticals in a research report on Tuesday, March 19th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Leerink Swann lowered Amneal Pharmaceuticals to a “market perform” rating in a research report on Friday, March 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $19.60.

In other news, Director Peter R. Terreri sold 23,345 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Pradeep Bhadauria purchased 7,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were bought at an average price of $8.48 per share, with a total value of $59,360.00. The disclosure for this purchase can be found here. Insiders have bought 58,000 shares of company stock valued at $590,790 over the last 90 days. Corporate insiders own 26.34% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $249,000. Menta Capital LLC acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $403,000. Legal & General Group Plc grew its holdings in Amneal Pharmaceuticals by 20.7% in the third quarter. Legal & General Group Plc now owns 32,695 shares of the company’s stock valued at $726,000 after purchasing an additional 5,596 shares during the period. Virtu Financial LLC acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $226,000. Finally, SG Americas Securities LLC acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $192,000. Institutional investors own 38.31% of the company’s stock.

Shares of Amneal Pharmaceuticals stock opened at $9.13 on Friday. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 9.61, a PEG ratio of 0.50 and a beta of 1.31. Amneal Pharmaceuticals has a 12 month low of $8.20 and a 12 month high of $24.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with's FREE daily email newsletter.